ADAR1 Capital Management LLC Makes New $1.29 Million Investment in Supernus Pharmaceuticals, Inc. $SUPN

Key Points

• ADAR1 Capital Management initiated a 27,842-share position in Supernus Pharmaceuticals during the second quarter, valued at approximately $1.29 million. Several other institutional investors also established or increased stakes.
• Analyst sentiment is mixed but leans positive, with Supernus carrying a consensus “Moderate Buy” rating and an average price target of $62.83, compared with its reported opening price of $45.36.
• Supernus beat quarterly revenue expectations, reporting $219.06 million—up 32.4% year over year—but posted an adjusted loss of $1.01 per share versus the expected $0.42 profit.

ADAR1 Capital Management LLC purchased a new stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 27,842 shares of the specialty pharmaceutical company's stock, valued at approximately $1,295,000.

Other institutional investors have also recently modified their holdings of the company. Hsbc Holdings PLC acquired a new position in Supernus Pharmaceuticals during the second quarter worth about $424,000. PDT Partners LLC purchased a new stake in shares of Supernus Pharmaceuticals in the second quarter valued at about $1,203,000. Canada Pension Plan Investment Board purchased a new stake in shares of Supernus Pharmaceuticals in the second quarter valued at about $823,000. Legal & General Group Plc acquired a new stake in shares of Supernus Pharmaceuticals in the second quarter valued at approximately $6,299,000. Finally, The Manufacturers Life Insurance Company purchased a new position in Supernus Pharmaceuticals during the second quarter worth $1,298,000.

Wall Street Analysts Forecast Growth

SUPN has been the subject of several analyst reports. Weiss Ratings reissued a "sell (d+)" rating on shares of Supernus Pharmaceuticals in a research note on Wednesday, June 24th. Wall Street Zen cut shares of Supernus Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Saturday, August 8th. Cantor Fitzgerald raised their price target on Supernus Pharmaceuticals from $63.00 to $67.00 and gave the stock an "overweight" rating in a research note on Thursday, July 9th. Finally, Zacks Research upgraded Supernus Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a report on Thursday, August 6th. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, Supernus Pharmaceuticals currently has an average rating of "Moderate Buy" and a consensus price target of $62.83.

Supernus Pharmaceuticals Stock Performance

SUPN stock opened at $45.36 on Wednesday. The firm has a market cap of $2.64 billion, a P/E ratio of -23.62, a price-to-earnings-growth ratio of 0.83 and a beta of 0.56. Supernus Pharmaceuticals, Inc. has a 1 year low of $42.45 and a 1 year high of $59.68. The stock has a 50-day simple moving average of $46.80 and a 200-day simple moving average of $48.78.

Supernus Pharmaceuticals (NASDAQ:SUPN - Get Free Report) last released its quarterly earnings results on Monday, August 3rd. The specialty pharmaceutical company reported ($1.01) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.42 by ($1.43). Supernus Pharmaceuticals had a positive return on equity of 11.13% and a negative net margin of 13.23%.The firm had revenue of $219.06 million for the quarter, compared to analysts' expectations of $205.31 million. During the same period last year, the firm earned $0.40 EPS. The business's quarterly revenue was up 32.4% on a year-over-year basis. On average, equities research analysts predict that Supernus Pharmaceuticals, Inc. will post 1.97 EPS for the current year.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company's marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source